Prevalence and Correlates of the Estrogen and Progesterone Receptors (ER/PR), Human Epidermal Growth Factor Receptor-2 (HER-2) and P53 in Breast Cancer: a Cross-Sectional Study
نویسندگان
1 Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
2 Department of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
3 Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
4 Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
5 Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
doi
10.30699/jogcr.7.6.507چکیده
Background & Objective: Breast cancer has a pivotal role in many deaths caused by malignancies. Epidermal growth factor receptor-2 (EGFR-2 or HER-2) and estrogen receptor (ER) have immense predictive values as prognostic factors. Breast cancers that have steroid receptors and respond to hormone therapy show a better prognosis than cancers without steroid receptors.Materials & Methods: A retrospective cross-sectional study was performed on 500 pathology blocks of women with breast cancer sent to the pathology department of Amir-al-Momenin medical and educational center, Gerash, Iran, from 2016 to 2019. Data were analyzed by SPSS software (Version-16) via ANOVA test followed by Chi-square and t-tests. P-value <0.05 was considered as significant.Results: The utmost type of malignancy was invasive ductal carcinoma (IDC) at 35.03%. Among ER-positive patients 59.67% were HER-2-positive. Nonetheless, among the PR-positive patients 54.74% were HER-2-positive. ER-positive patients were correlated with p53 receptor, distant metastasis and HER-2 significantly (P < /i><0.01). However, PR-positive patients just correlated with p53 receptor significantly (P < /i><0.01).Conclusion: Investigated samples were more ER-negative and less PR-positive compared to similar studies. Meanwhile, ER-positive patients were HER-2-positive. Regarding the correlation with prognosis of breast cancer, especially in HER-2-positive patients, there is a need to perform profound screening programs for HER-2 in breast cancer patients, especially with histopathological characteristics of invasive ductal carcinoma.
